IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen G, Li Z, et al. Colonoscopic screening is associated with reduced Colorectal Cancer incidence and mortality: a systematic review and meta-analysis. J Cancer. 2020;11(20):5953–5970. doi:10.7150/jca.46661
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. doi:10.3322/caac.21349
   PubMed Web of Science ®Google Scholar
• Hull R, Francies FZ, Oyomno M,et al. Incidence and risk factors: in search for targeted therapies. Cancer Manag Res. 2020;12(12):9869–9882. doi:10.2147/CMAR.S251223
   PubMedGoogle Scholar
• Nasser NJ, Gorenberg M, Agbarya A. First line immunotherapy for non-small cell lung cancer. Pharmaceuticals (Basel). 2020;13(11):E373. doi:10.3390/ph13110373
   PubMedGoogle Scholar
• Kuryk L, Bertinato L, Staniszewska M, et al. From conventional therapies to immunotherapy: melanoma treatment in Review. Cancers (Basel). 2020;12(10):3057. doi:10.3390/cancers12103057
   PubMed Web of Science ®Google Scholar
• Aly R, Aujla AS, Gupta S, et al. Evolving paradigms in the management and outcomes of sarcomatoid renal cell carcinoma in the era of immune checkpoint inhibitors. World J Oncol. 2020;11(5):183–187. doi:10.14740/wjon1325
   PubMedGoogle Scholar
• Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017;66(5):551–564. doi:10.1007/s00262-017-1954-6
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers. 2004;20(4–5):199–206. doi:10.1155/2004/368680
   PubMed Web of Science ®Google Scholar
• Marmorino F, Boccaccino A, Germani MM, et al. Immune checkpoint inhibitors in pMMR metastatic colorectal cancer: a tough challenge. Cancers (Basel). 2020;12(8):2317. doi:10.3390/cancers12082317
   PubMed Web of Science ®Google Scholar
• Jácome AA, Eng C. Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. Expert Opin Biol Ther. 2019;19(12):1247–1263. doi:10.1080/14712598.2019.1680636
   PubMed Web of Science ®Google Scholar
• Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 2015;51(3):221–228. doi:10.1016/j.oraloncology.2014.11.014
   PubMed Web of Science ®Google Scholar
• Kursunel MA, Esendagli G. The untold story of IFN-γ in cancer biology. Cytokine Growth Factor Rev. 2016;31:73–81. doi:10.1016/j.cytogfr.2016.07.005
   PubMed Web of Science ®Google Scholar
• Mimura K, Teh JL, Okayama H, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018;109(1):43–53. doi:10.1111/cas.13424
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Gonzalez-Cao M, Crespo G, et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol. 2018;10:1758834017749748. doi:10.1177/1758834017749748
   Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–829. doi:10.1056/NEJMoa1604958
   PubMed Web of Science ®Google Scholar
• Shin DS, Zaretsky JM, Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7(2):188–201. doi:10.1158/2159-8290.CD-16-1223
   PubMed Web of Science ®Google Scholar
• Eriksen AC, Sørensen FB, Lindebjerg J, et al. Programmed death ligand-1 expression in stage II colon cancer - experiences from a nationwide population based cohort. BMC Cancer. 2019;19(1):142. doi:10.1186/s12885-019-5345-6
   PubMedGoogle Scholar
• Salem ME, Puccini A, Grothey A, et al. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol Cancer Res. 2018;16(5):805–812. doi:10.1158/1541-7786.MCR-17-0735
   PubMed Web of Science ®Google Scholar
• Roberts J, Salaria SN, Cates J, et al. PD-L1 expression patterns in microsatellite instability-high intestinal adenocarcinoma subtypes. Am J Clin Pathol. 2019;152(3):384–391. doi:10.1093/ajcp/aqz052
   PubMed Web of Science ®Google Scholar
• Emambux S, Tachon G, Junca A, et al. Results and challenges of immune checkpoint inhibitors in colorectal cancer. Expert Opin Biol Ther. 2018;18(5):561–573. doi:10.1080/14712598.2018.1445222
   PubMed Web of Science ®Google Scholar
• Yaghoubi N, Soltani A, Ghazvini K, et al. PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312–318. doi:10.1016/j.biopha.2018.11.105
   PubMed Web of Science ®Google Scholar
• Yuan W, Deng D, Jiang H, et al. Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer. Cancer Immunol Immunother. 2019;68(2):257–268. doi:10.1007/s00262-018-2270-5
   PubMed Web of Science ®Google Scholar
• Wei XL, Wu QN, Chen DL, et al. The clinical and biomarker association of programmed death ligand 1 and its spatial heterogeneous expression in colorectal cancer. J Cancer. 2018;9(23):4325–4333. doi:10.7150/jca.27735
   PubMed Web of Science ®Google Scholar
• Zhang S, Kohli K, Black RG, et al. Systemic interferon-γ increases MHC class I expression and T-cell infiltration in cold tumors: results of a Phase 0 Clinical Trial. Cancer Immunol Res. 2019;7(8):1237–1243. doi:10.1158/2326-6066.CIR-18-0940
   PubMed Web of Science ®Google Scholar
• Lastwika KJ, Wilson W, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76(2):227–238. doi:10.1158/0008-5472.CAN-14-3362
   PubMed Web of Science ®Google Scholar
• Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, et al. MET-oncogenic and JAK2-inactivating alterations are independent factors that affect Regulation of PD-L1 expression in lung cancer. Clin Cancer Res. 2018;24(18):4579–4587. doi:10.1158/1078-0432.CCR-18-0267
   PubMed Web of Science ®Google Scholar
• Imai Y, Chiba T, Kondo T, et al. Interferon-gamma induced PD-L1 expression and soluble PD-L1 production in gastric cancer. Oncol Lett. 2020;20(3):2161–2168. doi:10.3892/ol.2020.11757
   PubMed Web of Science ®Google Scholar
• Zhao T, Li Y, Zhang J, et al. PD-L1 expression increased by IFN-gamma via JAK2-STAT1 signaling and predicts a poor survival in colorectal cancer. Oncol Lett. 2020;20(2):1127–1134. doi:10.3892/ol.2020.11647
   PubMed Web of Science ®Google Scholar
• Hänze J, Wegner M, Noessner E, et al. Co-regulation of immune checkpoint PD-L1 with interferon-gamma signaling is associated with a survival benefit in renal cell cancer. Target Oncol. 2020;15(3):377–390. doi:10.1007/s11523-020-00728-8
   PubMed Web of Science ®Google Scholar
• Iwasa M, Harada T, Oda A, et al. PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-gamma. Oncotarget. 2019;10(20):1903–1917. doi:10.18632/oncotarget.26726
   PubMedGoogle Scholar
• Tong L, Li J, Li Q, et al. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics. 2020;10(13):5943–5956. doi:10.7150/thno.41498
   PubMed Web of Science ®Google Scholar
• Tripathi SC, Peters HL, Taguchi A, et al. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A. 2016;113(11):E1555–1564. doi:10.1073/pnas.1521812113
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Matsumura N, et al. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21(3):462–473. doi:10.1007/s10147-016-0959-z
   PubMed Web of Science ®Google Scholar
• Razi S, Baradaran Noveiry B, Keshavarz-Fathi M, et al. IL-17 and colorectal cancer: from carcinogenesis to treatment. Cytokine. 2019;116:7–12. doi:10.1016/j.cyto.2018.12.021
   PubMed Web of Science ®Google Scholar
• Yan R, Yang X, Wang X, et al. Association between intra-tumoral immune response and programmed death ligand 1 (PD-L1) in Gastric Cancer. Med Sci Monit. 2019;25:6916–6921. doi:10.12659/MSM.916432
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. doi:10.1158/2159-8290.CD-14-0863
   PubMed Web of Science ®Google Scholar